Tofacitinib in a methotrexate background was shown to have similar efficacy compared to TNF inhibitor adalimumab in RA patients with active disease despite conventional synthetic disease-modifying drug (csDMARD) treatment [10]. Here, TNF is linked to rheumatoid arthritis.